A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception

Human Reproduction

Volumn 30, Issue 12, 2015, Pages 2785-2793

  Brache, V ^a   Cochon, L ^a   Duijkers, I J M ^b   Levy, D P ^c   Kapp, N ^c   Monteil, C ^c   Abitbol, J L ^c   Klipping, C ^b  

^a PROFAMILIA   (Dominica)

^b Dinox BV   (Netherlands)

^c Laboratoire HRA Pharma   (France)

Author keywords

Emergency contraception; Progesterone receptor modulator; Progestin only pills; Quickstart; UPA

Indexed keywords

DESOGESTREL; PLACEBO; ULIPRISTAL; ORAL CONTRACEPTIVE AGENT; PREGNANE DERIVATIVE;

ADULT; ARTICLE; CONSENSUS; CONTROLLED STUDY; CORPUS LUTEUM; CROSSOVER PROCEDURE; DOMINICAN REPUBLIC; EMERGENCY CONTRACEPTION; FEMALE; HUMAN; NETHERLANDS; NORMAL HUMAN; OVULATION; PILL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEXUAL INTERCOURSE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SPERMATOZOON PENETRATION; UNPROTECTED SEX; ADOLESCENT; CLINICAL TRIAL; DRUG EFFECTS; MULTICENTER STUDY; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CONTRACEPTION, POSTCOITAL; CONTRACEPTIVES, ORAL, SYNTHETIC; CROSS-OVER STUDIES; DESOGESTREL; DOMINICAN REPUBLIC; FEMALE; HUMANS; NETHERLANDS; NORPREGNADIENES; OVULATION; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84983094502     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dev241     Document Type: Article

References (27)

1. Baerwald AR, Olatunbosun OA, Pierson RA. Effects of oral contraceptives administered at defined stages of ovarian follicular development. Fertil Steril 2006;86:27-35.
2. Brache V, Alvarez F, Cochon L, Thevenin F, Faundes A. Effect of preovulatory insertion of Norplant implants over luteinizing hormone secretion and folicular development. Fertil Steril 1996;65:1110-1114.
3. Brache V, Blumenthal PD, Alvarez F, Dunson TR, Cochon L, Faundes A. Timing of onset of contraceptive effectiveness in Norplant Implant Users II: effect on the ovarian function in the first cycle of use. Contraception 1999;59:245-251.
4. Brache V, Cochon L, Jesam C, Maldonado R, Salvatierra AM, Levy DP, Gainer E, Groxatto HB. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod 2010;25:2256-2263.
5. Brache V, Cochon L, Deniaud M, Croxatto HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 2013;88:611-618.
6. Cameron ST, Berger C, Michie L, Klipping C, Gemzell-Danielsson K. The effects on ovarian activity of 'quickstarting' a combined oral contraceptive pill after ulipristal acetate: prospective, randomised, double-blind parallel-arm, placebo-controlled study. Hum Reprod 2015;30:1566-1572.
7. Center of Disease Control and Prevention. US selective practice recommendations for contraceptive use. 2013. www. cdc. gov/mmwr/ preview/mmwrhtml/rr6205a1. htm (8 November 2013, date last accessed).
8. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007;92:3582-3589.
9. Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J. Progesterone receptor modulator for emergency contraception; a randomized controlled trial. Obstet Gynecol 2006;108:1089-1097.
10. Dunson TR, Blumenthal PD, Alvarez F, Brache V, Cochon L, Dalberth B, Glover L, Remsburg R, Vu K, Katz D. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus. Fertil Steril 1998;69:258-266.
11. Faculty of Sexual and Reproductive Healthcare. Quick-start guidance. 2010. http://www. fsrh. org/pdfs/CEUGuidanceQuickStartingContraception. pdf (accessed March 2015, date last accessed).
12. Faculty of Sexual and Reproductive Healthcare. Progestogens-only pills. 2015. http://www. fsrh. org/pdfs/CEUGuidanceProgestogenOnlyPills. pdf (accessed June 2015, date last accessed).
13. Fine P, Mathé H, Ginde S, Cullins V, Morfesis J, Gainer E. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet Gynecol 2010;115:257-263.
14. Glasier AF, Cameron ST, Fine PM, Logan SJ, CasaleW, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and meta-analysis. Lancet 2010;375:555-562.
15. Glasier A, Cameron ST, Blithe D, Scherrer B, Mathe H, Levy D, Gainer E, Ulmann A. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011;84:363-367.
16. Gould JE, OverstreetJW, HansonFW. Assessment of human sperm function after recovery from the female reproductive tract. Biol Reprod 1984; 31:888-894.
17. Jesam C, Cochon L, Salvatierra AM, Williams A, Brache V. A prospective, open-label, multicenter study to assess the pharmacodynamics and safety of repeated use of 30 mg ulipristal acetate. Contraception 2015; submitted for publication.
18. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994;50:S159-S188.
19. Nallasamy S, Kim J, Sitruk-Ware R, Bagchi M, Bagchi I. Ulipristal blocks ovulation by inhibiting progesterone receptor-dependent pathways intrinsic to the ovary. Reprod Sci 2013;20:371-381.
20. Petta CA, Faundes A, Dunson TR, Ramos M, DeLucio M, Faundes D, Bahamondes L. Timing of onset of contraceptive effectivness in Depo-Provera users: Part I. Changes in cervical mucus. Fertil Steril 1998a;69:252-257.
21. Petta CA, Faundes A, Dunson TR, Ramos M, DeLucio M, Faundes D, Bahamondes L. Timing of onset of contraceptive effectiveness in Depo-Provera users II Effects on ovarian function. Fertil Steril 1998b; 70:817-820.
22. Phillips A, Desmaret K, HahnDW, Wong F, McGuire JL. Progestational and androgenic receptor binDing affinities and in vivo activities of norgestimate and other progestins. Contraception 1990;41:399-410.
23. Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17b-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception 2013;87:706-726.
24. Stratton P, Hartog B, Hajizadeh N, Piquion J, Sutherland D, Merino M, Lee YJ, Nieman LK. Asingle mid-follicular dose of CDB-2914, a newantiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod 2000;15:1092-1099.
25. vanHeusen AM, Killick SR, Coelingh Bennink HJT, Fauser BCJM. Single monthly administration of the anti-progestagen Org 31710 in users of the 75 mg DSG progestagen-only pill: effects on pituitary-ovarian activity. Hum Reprod 2000;15:629-636.
26. World Health Organization, Department of Reproductive Health and Research. WHO laboratory manual for the examination and processing of human semen, 5th edn. World Health Organization, 2010.
27. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 1995;333:1517-1521.